Antiangiogenic treatment prevents adventitial constrictive remodeling in graft arteriosclerosis

Area of Science:

• Vascular Biology
• Immunology
• Transplantation Science

Background:

• Graft arteriosclerosis involves neointima formation and arterial remodeling due to inflammation and collagen deposition.
• Constrictive arterial remodeling, driven by adventitial inflammation, leads to lumen loss in grafts.
• Blocking inflammatory entry points is a potential strategy to prevent arterial remodeling.

Purpose of the Study:

• To investigate the efficacy of anti-angiogenic therapy in preventing graft arteriosclerosis.
• To determine if targeting angiogenesis can reduce adventitial inflammation and collagen deposition.
• To assess the impact of anti-angiogenic therapy on constrictive arterial remodeling and lumen surface area.

Main Methods:

• Utilized a rat aortic interposition model of graft arteriosclerosis.
• Administered ABT-510 nonapeptide, an anti-angiogenic agent without direct immunomodulatory effects.
• Quantified adventitial angiogenesis, inflammatory cell infiltration, collagen deposition, and lumen surface area.

Main Results:

• ABT-510 nonapeptide significantly reduced adventitial angiogenesis by 66% (P<0.0001).
• This led to decreased inflammatory cell entry (44%; P<0.00001) and reduced collagen deposition (57%; P<0.0001).
• ABT-510 prevented constrictive remodeling and lumen surface area reduction, without affecting neointima development.

Conclusions:

• Targeting angiogenesis with ABT-510 effectively prevents graft arteriosclerosis progression.
• Anti-angiogenic therapy acts by reducing adventitial inflammation and collagen deposition.
• This strategy may synergize with immunosuppressants to prevent chronic graft rejection.